Key Takeaway: Damora Therapeutics has initiated the Phase 1/1b CLARITY-101 clinical trial for DMR-001, targeting patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis. The company also presented promising preclinical data at the European Hematology Association 2026 Congress, highlighting its potential as a best-in-class treatment.
Market Sentiment Analysis
POSITIVE FACTORS
Initiation of Phase 1/1b clinical trial for DMR-001.
Presentation of preclinical data at a prominent congress.
Focus on mutant calreticulin-driven diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~75 mo
Minimal dilution risk
Lead asset
PAT-1251
Phase 1 · Healthy
Full Press Release Details
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the European Hematology Association (EHA) 2026 Congress, showcasing best-in-class
Frequently Asked Questions
What is the CLARITY-101 clinical trial?
The CLARITY-101 trial is a Phase 1/1b study of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.
Where was DMR-001 data presented?
DMR-001 preclinical data was presented at the European Hematology Association 2026 Congress.
What diseases does DMR-001 target?
DMR-001 targets essential thrombocythemia and myelofibrosis driven by mutant calreticulin.